Novartis Ag

Novartis Corporation

Sandoz Gmbh

Friedrich Richter

Armin Meinzer

Ulrich Posanski

Birgit Hauer

Barbara Haeberlin

Patrice Guitard

Rainer Link

Thomas Kissel

David Bodmer

Jacky Vonderscher

Harry Tiemessen

Fritz Schmook

Xue-Ping Popp

Martin Jackman

Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva]-Ciclosporin, in 'microemulsion pre-concentrate' and microemulsion form. The compositions typically comprise (1.1) a Calkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.

Pharmaceutical compositions comprising cyclosporins

A pharmaceutical composition in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin or an ascomycin, and a carrier medium.

Pharmaceutical compositions comprising 33-epi-chloro-33-desoxy-ascomycin solid dispersions

Allylamine-containing liposomes

Pharmaceutical compositions

A pharmaceutical composition in the form of an emulsion preconcentrate for oral administration and containing a cyclosporin. The pharmaceutical composition has a carrier medium for the cyclosporin that contains a hydrophilic organic solvent; a mixed mono-, di-, and tri-glyceride or a transesterified and polyethoxylated vegetable oil; and a polyoxyethylene-sorbitan-fatty acid ester surfactant. The pharmaceutical composition provides high bioavailability and low inter- and intra-subject variability.

Pharmaceutical compositions containing cyclosporins

Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in 'microemulsion pre-concentrate' and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 -alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.

Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in 'microemulsion pre-concentrate' and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.

Pharmaceutical compositions comprising rafamycin coprecipitates

Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or �Nva!.sup.2 -Ciclosporin, in 'microemulsion pre-concentrate' and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.

Growing community of inventors

Grenzach-Wyhlen, Germany

Friedrich Richter